Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.45 |
| ▸ | MMP13 | P45452 | 5/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402268 | 0.84 | MMP1 (0.43) | MMP1MMP13MMP9MMP3MMP7 | |
| SCHEMBL5068449 | 0.81 | MMP1 (0.39) | MMP1MMP13MMP9MMP3MMP7 | |
| SCHEMBL4404075 | 0.81 | MMP1 (0.39) | MMP1MMP13MMP9MMP3MMP7 | |
| SCHEMBL4459789 | 0.81 | MMP1 (0.41) | MMP1MMP13MMP9MMP3MMP7 | |
| SCHEMBL2916330 | 0.76 | CHRNB2 (0.39) | MMP1MMP13MMP9MMP3MMP7 | |
| SCHEMBL15432299 | 0.73 | CHRNB2 (0.37) | MMP1MMP13MMP9MMP3MMP7 | |
| SCHEMBL954492 | 0.73 | CHRNB2 (0.37) | MMP1MMP13MMP9MMP3MMP7 | |
| SCHEMBL29789488 | 0.73 | MMP2 (0.39) | MMP1MMP13MMP9MMP3MMP7 | |
| SCHEMBL2920031 | 0.70 | MMP1 (0.37) | MMP1MMP13MMP9MMP3MMP7 | |
| SCHEMBL26614323 | 0.70 | MMP1 (0.42) | MMP1MMP13MMP9MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | MMP1 626/4885MMP13 553/4885MMP9 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.